U.S. markets open in 3 hours 37 minutes

Amryt Pharma plc (AMYT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.74-0.05 (-0.42%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close11.79
Open11.75
Bid0.00 x 1200
Ask0.00 x 900
Day's Range11.58 - 11.82
52 Week Range10.06 - 15.50
Volume67,500
Avg. Volume67,592
Market Cap421.264M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
    GlobeNewswire

    Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.

    Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc. DUBLIN, Ireland, and Boston MA, June 15, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces it has filed a registration statement on Form F-4 (the "Registration Statement"), which contains a preliminary proxy st

  • 10 Best Stocks to Buy According to Highbridge Capital
    Insider Monkey

    10 Best Stocks to Buy According to Highbridge Capital

    In this article we will take a look at the 10 best stocks to buy according to billionaire Glenn Russell Dubin’s Highbridge Capital Management. You can skip our detailed analysis of Dubin’s history, investment philosophy, and hedge fund performance, and go directly to the 5 Best Stocks to Buy According to Billionaire Glenn Russell Dubin’s […]

  • FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
    GlobeNewswire

    FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting

    FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting DUBLIN, Ireland, and Boston MA, June 7, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the U.S. Food and Drug Administration (“FDA”) has confirmed that Amryt’s New Drug Application (“NDA”) for Oleogel-S10 for the treatment of Epidermolysis Bullosa (“EB”) will not